Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (46)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by D'Atri, S.
Right arrow Articles by Bonmassar, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by D'Atri, S.
Right arrow Articles by Bonmassar, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 6:389-393, 1995
© 1995 European Society for Medical Oncology

research-article

Chemosensitivity to triazene compounds and O6-alkylguanine-DNA alkyltransferase levels: Studies with blasts of leukaemic patients

S. D'Atri1,, D. Piccioni2, A. Castellano2, V. Tuorto2, A. Franchi2, K. Lu3, N. Christiansen3, S. Frankel3, Y. M. Rustum3, G. Papa4, F. Mandelli5 and E. Bonmassar1,6

1Istituto Dermopatico dell'Immacolata (IDI)
2Department of Experimental Medicine and Biochemical Sciences, University of Rome ‘Tor Vergata’ Rome, Italy
3Roswell Park Cancer Institute Buffalo, NY, U.S.A.
4Department of Internal Medicine, University of Rome ‘Tor Vergata’
5Department of Biopathology, University of Rome ‘La Sapienza’
6Institute of Experimental Medicine, National Council of Research Rome, Italy

Correspondence to: Stefania D'Atri, M.D., Istituto Dermopatico dell'Immacolata (IDI), Via dei Monti di Creta 104, 00167 Rome, Italy

BACKGROUND: clinical pilot study performed by our group showed that dacarbazine can induce a marked reduction of blast cells in patients with acute myelogenous leukaemia (AML). Leukaemic blasts (LB) from responsive patients showed low levels of O6-alkylguanine-DNA alkyltransferase(OGAT).

DESIGN: An in vitro study was performed to evaluate OGAT levels and sensitivity to temozolomide (a triazene compound that spontaneously decomposes into the active metabolite of dacarbazine) in a relatively large number of LB samples.

RESULTS: OGAT levels varied widely among the LB of different patients, with a mean value higher in acute lymphoblastic leukaemias than in AML. About 25% of LB obtained from patients with AML showed low OGAT activity, in the range corresponding to that observed in leukaemic patients responsive to dacarbazine in vivo. A reasonable inverse correlation was found between OGAT levels and LB sensitivity to temozolomide.

CONCLUSIONS: Triazenes could have a therapeutic potential in human leukaemias. Moreover, OGAT determination could provide rapid and reliable information about a patient's susceptibility to these antitumor agents.

alkyltransferase, chemosensitivity, leukaemia, triazenes


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
T. M. Horton, P. A. Thompson, S. L. Berg, P. C. Adamson, A. M. Ingle, M. E. Dolan, S. M. Delaney, M. Hedge, H. L. Weiss, M.-F. Wu, et al.
Phase I Pharmacokinetic and Pharmacodynamic Study of Temozolomide in Pediatric Patients With Refractory or Recurrent Leukemia: A Children's Oncology Group Study
J. Clin. Oncol., November 1, 2007; 25(31): 4922 - 4928.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. Giles, D. Rizzieri, J. Karp, N. Vey, F. Ravandi, S. Faderl, K. Dad Khan, G. Verhoef, P. Wijermans, A. Advani, et al.
Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, in Patients Age 60 Years or Older With Previously Untreated Acute Myeloid Leukemia
J. Clin. Oncol., January 1, 2007; 25(1): 25 - 31.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
D. M. Kokkinakis, A. G. Brickner, J. M. Kirkwood, X. Liu, J. E. Goldwasser, A. Kastrama, C. Sander, D. Bocangel, and S. Chada
Mitotic Arrest, Apoptosis, and Sensitization to Chemotherapy of Melanomas by Methionine Deprivation Stress
Mol. Cancer Res., August 1, 2006; 4(8): 575 - 589.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Giles, S. Verstovsek, D. Thomas, S. Gerson, J. Cortes, S. Faderl, A. Ferrajoli, F. Ravandi, S. Kornblau, G. Garcia-Manero, et al.
Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia
Clin. Cancer Res., November 1, 2005; 11(21): 7817 - 7824.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
D. Bafaloukos, D. Tsoutsos, H. Kalofonos, S. Chalkidou, P. Panagiotou, E. Linardou, E. Briassoulis, E. Efstathiou, A. Polyzos, G. Fountzilas, et al.
Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group
Ann. Onc., June 1, 2005; 16(6): 950 - 957.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Giles, D. Thomas, G. Garcia-Manero, S. Faderl, J. Cortes, S. Verstovsek, A. Ferrajoli, S. Jeha, M. Beran, C. Koller, et al.
A Phase I and Pharmacokinetic Study of VNP40101M, a Novel Sulfonylhydrazine Alkylating Agent, in Patients with Refractory Leukemia
Clin. Cancer Res., May 1, 2004; 10(9): 2908 - 2917.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
Y. Hirose, M. Katayama, D. Stokoe, D. A. Haas-Kogan, M. S. Berger, and R. O. Pieper
The p38 Mitogen-Activated Protein Kinase Pathway Links the DNA Mismatch Repair System to the G2 Checkpoint and to Resistance to Chemotherapeutic DNA-Methylating Agents
Mol. Cell. Biol., November 15, 2003; 23(22): 8306 - 8315.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. Seiter, D. Liu, T. Loughran, A. Siddiqui, P. Baskind, and T. Ahmed
Phase I Study of Temozolomide in Relapsed/Refractory Acute Leukemia
J. Clin. Oncol., August 1, 2002; 20(15): 3249 - 3253.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Hirose, M. S. Berger, and R. O. Pieper
p53 Effects Both the Duration of G2/M Arrest and the Fate of Temozolomide-treated Human Glioblastoma Cells
Cancer Res., March 1, 2001; 61(5): 1957 - 1963.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
H. S. Friedman, T. Kerby, and H. Calvert
Temozolomide and Treatment of Malignant Glioma
Clin. Cancer Res., July 1, 2000; 6(7): 2585 - 2597.
[Abstract] [Full Text]

Home page
 JCOHome page
M. R. Middleton, J. J. Grob, N. Aaronson, G. Fierlbeck, W. Tilgen, S. Seiter, M. Gore, S. Aamdal, J. Cebon, A. Coates, et al.
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
J. Clin. Oncol., January 5, 2000; 18(1): 158 - 158.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
E. Alvino, R. Pepponi, E. Pagani, P. M. Lacal, C. Nunziata, E. Bonmassar, and S. D'Atri
O6-Benzylguanine Enhances the In Vitro Immunotoxic Activity of Temozolomide on Natural or Antigen-Dependent Immunity
J. Pharmacol. Exp. Ther., December 1, 1999; 291(3): 1292 - 1300.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
C. D. Britten, E. K. Rowinsky, S. D. Baker, S. S. Agarwala, J. R. Eckardt, R. Barrington, S. G. Diab, L. A. Hammond, T. Johnson, M. Villalona-Calero, et al.
A Phase I and Pharmacokinetic Study of Temozolomide and Cisplatin in Patients with Advanced Solid Malignancies
Clin. Cancer Res., July 1, 1999; 5(7): 1629 - 1637.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
L. Tentori, P. M. Lacal, E. Benincasa, D. Franco, I. Faraoni, E. Bonmassar, and G. Graziani
Role of Wild-Type p53 on the Antineoplastic Activity of Temozolomide Alone or Combined with Inhibitors of Poly(ADP-Ribose) Polymerase
J. Pharmacol. Exp. Ther., May 1, 1998; 285(2): 884 - 893.
[Abstract] [Full Text]

Home page
 Mol. Pharmacol.Home page
L. Tentori, L. Orlando, P. M. Lacal, E. Benincasa, I. Faraoni, E. Bonmassar, S. D'Atri, and G. Graziani
Inhibition of O6-Alkylguanine DNA-Alkyltransferase or Poly(ADP-ribose) Polymerase Increases Susceptibility of Leukemic Cells to Apoptosis Induced by Temozolomide
Mol. Pharmacol., August 1, 1997; 52(2): 249 - 258.
[Abstract] [Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.